About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Liquid Biopsy Market Size, Global Trends, Share, Forecast to 2033
Liquid Biopsy Market

Liquid Biopsy Market Size, Share & Trends Analysis Report By Product and Services (Kits and Reagents, Platforms and Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA]), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer), By End-User (Hospitals and Laboratories, Government and Academic Research Centers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI2082DR
Last Updated : November 12, 2024
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Liquid Biopsy Market Introduction
    2. By Product and Services
      1. Introduction
        1. Product and Services By Value
      2. Kits and Reagents
        1. By Value
      3. Platforms and Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA [ctDNA]
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Liver Cancer
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Laboratories
        1. By Value
      3. Government and Academic Research Centers
        1. By Value
    1. Introduction
    2. By Product and Services
      1. Introduction
        1. Product and Services By Value
      2. Kits and Reagents
        1. By Value
      3. Platforms and Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA [ctDNA]
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Liver Cancer
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Laboratories
        1. By Value
      3. Government and Academic Research Centers
        1. By Value
    6. U.S.
      1. By Product and Services
        1. Introduction
          1. Product and Services By Value
        2. Kits and Reagents
          1. By Value
        3. Platforms and Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA [ctDNA]
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Liver Cancer
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Laboratories
          1. By Value
        3. Government and Academic Research Centers
          1. By Value
    7. Canada
    1. Introduction
    2. By Product and Services
      1. Introduction
        1. Product and Services By Value
      2. Kits and Reagents
        1. By Value
      3. Platforms and Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA [ctDNA]
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Liver Cancer
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Laboratories
        1. By Value
      3. Government and Academic Research Centers
        1. By Value
    6. U.K.
      1. By Product and Services
        1. Introduction
          1. Product and Services By Value
        2. Kits and Reagents
          1. By Value
        3. Platforms and Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA [ctDNA]
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Liver Cancer
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Laboratories
          1. By Value
        3. Government and Academic Research Centers
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Product and Services
      1. Introduction
        1. Product and Services By Value
      2. Kits and Reagents
        1. By Value
      3. Platforms and Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA [ctDNA]
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Liver Cancer
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Laboratories
        1. By Value
      3. Government and Academic Research Centers
        1. By Value
    6. China
      1. By Product and Services
        1. Introduction
          1. Product and Services By Value
        2. Kits and Reagents
          1. By Value
        3. Platforms and Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA [ctDNA]
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Liver Cancer
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Laboratories
          1. By Value
        3. Government and Academic Research Centers
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Product and Services
      1. Introduction
        1. Product and Services By Value
      2. Kits and Reagents
        1. By Value
      3. Platforms and Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA [ctDNA]
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Liver Cancer
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Laboratories
        1. By Value
      3. Government and Academic Research Centers
        1. By Value
    6. UAE
      1. By Product and Services
        1. Introduction
          1. Product and Services By Value
        2. Kits and Reagents
          1. By Value
        3. Platforms and Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA [ctDNA]
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Liver Cancer
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Laboratories
          1. By Value
        3. Government and Academic Research Centers
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Product and Services
      1. Introduction
        1. Product and Services By Value
      2. Kits and Reagents
        1. By Value
      3. Platforms and Instruments
        1. By Value
      4. Services
        1. By Value
    3. By Circulating Biomarker
      1. Introduction
        1. Circulating Biomarker By Value
      2. Circulating Tumor Cells
        1. By Value
      3. Extracellular Vesicles
        1. By Value
      4. Circulating Tumor DNA [ctDNA]
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Liver Cancer
        1. By Value
    5. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals and Laboratories
        1. By Value
      3. Government and Academic Research Centers
        1. By Value
    6. Brazil
      1. By Product and Services
        1. Introduction
          1. Product and Services By Value
        2. Kits and Reagents
          1. By Value
        3. Platforms and Instruments
          1. By Value
        4. Services
          1. By Value
      2. By Circulating Biomarker
        1. Introduction
          1. Circulating Biomarker By Value
        2. Circulating Tumor Cells
          1. By Value
        3. Extracellular Vesicles
          1. By Value
        4. Circulating Tumor DNA [ctDNA]
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Liver Cancer
          1. By Value
      4. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals and Laboratories
          1. By Value
        3. Government and Academic Research Centers
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Liquid Biopsy Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Bio-Rad Laboratories Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Biocept Inc.
    3. Guardant Health Inc.
    4. Illumina Inc.
    5. Hoffmann-La Roche Ltd. (Foundation Medicine Inc.)
    6. Johnson & Johnson
    7. Laboratory Corporation of America Holdings
    8. Mdxhealth SA
    9. Qiagen N.V.
    10. Thermo Fisher Scientific Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global liquid soap market size was valued at USD 22,444 million in 2021, anticipated to project to USD 46,729 million in 2030 at a CAGR of 9.6% during the forecast period. Liquid soaps come in liquid form and can be used for various purpose
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.